Information about Liraglutide
Liraglutide is a once-daily human GLP-1 analogue. The compound is being developed by Novo Nordisk for the treatment of type 2 diabetes. Liraglutide works by stimulating the release of insulin only when glucose levels become too high 1,2, and by inhibiting appetite 3.
GLP-1 lowers blood glucose in type 2 diabetes patients with the unique advantage that glucose-lowering ceases when blood glucose gets into the normal range, as both effects on insulin and glucagon release are glucose-dependent 4,5,6,7. Thus, it is possible to treat effectively without simultaneously running a risk of inducing hypoglycaemia. GLP-1 has a positive impact on beta cell function 8,9,10. Also, in contrast to most other antidiabetic treatments, liraglutide also leads to weight loss, an important problem during current treatment of type 2 diabetes 11. Liraglutide also has a beneficial impact on systolic blood pressure, a key cardiovascular risk factor in type 2 diabetes 11,12.
Liraglutide is a derivative of human GLP-1 (97% homology) 13 designed to be protected against DPPIV degradation and elimination by the kidneys resulting in a prolonged half-life 14,15 and thus sustained action of more than 24 hours 16,17. This is primarily due to its binding to serum albumin.
Information about the LEAD programme
The LEAD® programme (Liraglutide Effect and Action in Diabetes) includes around 4,000 patients with type 2 diabetes whose blood glucose is inadequately controlled. The programme is comprised of five randomised, controlled, double-blind studies conducted in more than 40 countries.